Pejovic Tanja, Abate Pierre-Valérien, Ma Hongli, Thiessen Jaclyn, Corless Christopher L, Peterson Abigail, Allard-Chamard Hugues, Labrie Marilyne
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
Front Oncol. 2022 May 25;12:903806. doi: 10.3389/fonc.2022.903806. eCollection 2022.
Between 2% and 6% of epithelial ovarian cancer (EOC) patients develop brain metastases (brain mets), which are incurable and invariably result in death. This poor outcome is associated with a lack of established guidelines for the detection and treatment of brain mets in EOC patients. In this study, we characterize an unusual case of low-grade serous ovarian carcinoma (LGSOC) that metastasized to the brain. Using a spatially oriented single-cell proteomics platform, we compared sequential biopsies of a primary tumor with a peritoneal recurrence and brain mets. We identified several targetable oncogenic pathways and immunosuppressive mechanisms that are amplified in the brain mets and could be involved in the progression of LGSOC to the brain. Furthermore, we were able to identify cell populations that are shared between the primary tumor and the brain mets, suggesting that cells that have a propensity for metastasis to the brain could be identified early during the course of disease. Taken together, our findings further a path for personalized therapeutic decisions in LGSOC.
2%至6%的上皮性卵巢癌（EOC）患者会发生脑转移，这种情况无法治愈，最终必然导致死亡。这种糟糕的结局与缺乏针对EOC患者脑转移的检测和治疗的既定指南有关。在本研究中，我们描述了一例罕见的低级别浆液性卵巢癌（LGSOC）发生脑转移的病例。我们使用空间定位单细胞蛋白质组学平台，比较了原发性肿瘤与腹膜复发及脑转移灶的连续活检样本。我们确定了几种在脑转移灶中扩增且可能参与LGSOC向脑转移进展的可靶向致癌途径和免疫抑制机制。此外，我们能够识别原发性肿瘤和脑转移灶之间共有的细胞群，这表明在疾病过程早期就可以识别出有脑转移倾向的细胞。综上所述，我们的研究结果为LGSOC的个性化治疗决策开辟了一条道路。
